logo-loader

Botanix Pharmaceuticals raises $40mln to push its CBD-based skin disease treatments through the pipeline

Last updated: 15:02 01 Aug 2019 EDT, First published: 01:02 01 Aug 2019 EDT

Botanix Pharmaceuticals Limited (ASX:BOT) CEO Matt Callahan tells Proactive Investors the clinical-stage pharma company has raised $40 million.

Callahan says the cash will allow the Sydney, Australia, and Philadelphia, Pennsylvania-based company to accelerate its preclinical and clinical work in bringing its CBD-based skin disease treatments to phase 3. Additionally, these funds will allow the company to bring into the clinic its first application of CBD as a stand-alone antimicrobial. 

Ramp Metals Launches Drilling Program in Pursuit of High-Grade Nickel in...

Ramp Metals CEO Jordan Black joined Steve Darling from Proactive to introduce the company to the public domain and share exciting developments in the mining industry. With a background as a geotechnical engineer and experience in venture capital, including a notable role in taking GoldSpot...

43 minutes ago